clinical trial · NCT04877288
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
Bristol-Myers Squibb·phase3·recruiting·n = 102
Renal Allograft RecipientsBelataceptTacrolimusCyclosporine AMycophenolate MofetilEnteric Coated Mycophenolate SodiumCorticosteroids
brief summary
The purpose of this study is to evaluate the benefits and risks of conversion of existing adolescent kidney allograft recipients aged 12 to less than 18 years of age to a belatacept-based immunosuppressive regimen as compared to continuation of a calcineurin inhibitor-based regimen and their adherence to immunosuppressive medications.
started
Jul 21, 2021
primary completion
Dec 30, 2032
completion
Jun 30, 2034
last updated
Feb 3, 2026
official title
A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol